FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine Therapy for the Maintenance Treatment of HR-positive, HER2-positive LA/MBC By Ogkologos - July 29, 2026 159 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PATINA study Source RELATED ARTICLESMORE FROM AUTHOR A glucometer for cancer: towards a scalable, universal residual disease measurement Consensus-Defined Weight Loss Episodes Arise in Discrete Intervals, Are Enriched Around Progression and Associated with Serologic Signatures and Somatic Tumour Genotypes ESMO launches new principles for humanising scientific reporting to strengthen the communication of cancer research MOST POPULAR The future of research: meet three of our scientists working on... December 13, 2022 Licorice: The Unique Root With 10 Amazing Health Benefits August 21, 2019 Dr. Alan S. Rabson, Long-Time NCI Deputy Director and Cancer Research... July 5, 2018 EMA Recommends Extension of Indications for Ribociclib to Include Use in... November 5, 2024 Load more HOT NEWS Young Women with Breast Cancer Often Forgo Hormone Therapy Due to... FDA Approves Pralsetinib for Non-Small Cell Lung Cancer with RET Gene... EMA Recommends Granting a Conditional Marketing Authorisation for Belantamab Mafodotin 5-Year-Old Boy Battling Cancer Receives Dream Come True, Sworn In As...
